Lantheus acquires NAV 4694, a next-generation Beta Amyloid PET Imaging agent for Alzheimer’s disease.
Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company committed to enabling clinicians to deliver better patient outcomes, announced its acquisition of Meilleur Technologies, Inc., which includes NAV 4694, expanding Lantheus’ Alzheimer’s disease pipeline
Through this acquisition, Lantheus now has the worldwide exclusive rights to beta amyloid PET (positron emission tomography) imaging agent, NAV 4694, also known as F18-flutafuranol. NAV-4694 is currently in Phase III development and is also being used in academic and industry investigational therapeutic trials.
The acquisition of this asset broadens Lantheus’ Alzheimer’s diagnostic portfolio and complements Lantheus’ next generation F18-labeled PET imaging agent candidate, MK 6240 (also known as florquinitau), which targets tau tangles in Alzheimer’s disease.
Recently published updated guidelines developed by a working group of the National Institute on Aging and the Alzheimer's Association (NIA-AA) state that Alzheimer’s disease should be defined biologically, using protein-based biomarkers. These guidelines recommend that biomarkers, including both amyloid- and tau-PET imaging, may be used to diagnose Alzheimer's disease and provide an indication of its severity.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.